Skip to main content

Advertisement

SpringerLink
Log in

Advancing precision rheumatology through tissue and blood profiling

  • Comment
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

Multidimensional and single-cell profiling of peripheral blood and inflamed tissues is a powerful and high-resolution tool for the stratification of patients with autoimmune rheumatic diseases into distinct cellular and/or molecular endotypes. The road towards precision rheumatology is long, but the time has come to enter the territory of clinical validation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: A roadmap towards precision rheumatology.

References

  1. Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616–624 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tanaka, H. et al. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann. Rheum. Dis. 83, 242–252 (2024).

    Article  CAS  PubMed  Google Scholar 

  3. Mateo, J. et al. Delivering precision oncology to patients with cancer. Nat. Med. 28, 658–665 (2022).

    Article  CAS  PubMed  Google Scholar 

  4. Lin, C. M. A., Cooles, F. A. H. & Isaacs, J. D. Precision medicine: the precision gap in rheumatic disease. Nat. Rev. Rheumatol. 18, 725–733 (2022).

    Article  PubMed  Google Scholar 

  5. Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915–927 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305–317 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648–659 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nehar-Belaid, D. et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat. Immunol. 21, 1094–1106 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551–565 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital for Special Surgery, Arthritis & Tissue Degeneration, New York, NY, USA

    George D. Kalliolias

  2. Weill Cornell Medical College, Department of Medicine, New York, NY, USA

    George D. Kalliolias

  3. Regeneron Pharmaceuticals, Tarrytown, NY, USA

    George D. Kalliolias

  4. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Athanasios G. Papavassiliou

Authors
  1. George D. Kalliolias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasios G. Papavassiliou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanasios G. Papavassiliou.

Ethics declarations

Competing interests

G.D.K. is a full-time employee and shareholder at Regeneron Pharmaceuticals. A.G.P. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalliolias, G.D., Papavassiliou, A.G. Advancing precision rheumatology through tissue and blood profiling. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01115-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41584-024-01115-7

  • Springer Nature Limited

Search

Navigation